Hello,
I work at a clinic where GLP-1 drugs are prescribed more and more. I get many interesting studies emailed to me. Here's information that's available for all to read but not much talked about.
I guess this is what medicine's final destination looks like. When life sucks so bad that the majority of he people descends into binges of junk food, alcohol, drugs, gambling and the like, the solution medicine has is not to encourage people to identify the real problem but just give them the drugs that make people lose interest in those problems such as eating...and in life in general.
It seems that that part is considered just an "acceptable" side effect. Yes, as it turns out the blockbuster GLP-1 drugs are powerful inducers of anhedonia (a lack of interest, pleasure or general enjoyment of life). This is not only a core symptom of clinical depression, but is also notoriously hard to treat. BTW SSRI drugs are known to exacerbate rather than treat anhedonia. That little fact should tell you how "antidepressant" those drugs really are.
Back to anhedonia. This is very difficult to treat with existing drugs, losing pleasure/joy in life is one step away from giving up on life and many people attempt suicide after reaching that stage. Of course if something causes anhedonia that doesn't mean that it also causes depression in all cases. However if one digs deeper, the evidence quickly emerges that GLP-1 agonist drugs do in fact drastically increase the risk of ANY major psychiatric disorder, including clinical depression, and of course suicide.
I guess this is how medicine " treats" obesity, by causing people to lose interest in eating and eventually living. That means so many more psychiatric patients and (maybe hopefully?) fewer people overall. Yay for carbon reduction.
And for those unfortunate enough to have used or planning to use these drugs, if anhedonia ends up developing, it may be treatable by raising dopamine or using dopaminergic drugs, which once again suggests that anhedonia is nothing but a symptom of serotonin access, as serotonin is the master inducer of anhedonia.
[RFK Jr. Smeared as Fatphobic for Questioning Weight Loss Drugs | ZeroHedge](https://www.zerohedge.com/news/2024-12-12/ozempic-propaganda-roundup-rfk-jr-smeared-fatphobic-questioning-weight-loss-drugs)
_“**Eli Lilly**, the company that makes the blockbuster weight loss treatment Zepbound, **will start studying its obesity products as treatments for alcohol and drug abuse**, making it the first major drugmaker to do so, **CEO David Ricks said** Tuesday._
_Emerging research suggests that **GLP-1 drugs** — Zepbound is one such treatment — **not only reduce food cravings but may also suppress desires for other substances**. Yet, so far, no pharma companies have tested the therapies specifically in addiction._
_“**These medicines, we think and we’ve aimed to prove, can be useful for other things we don’t think about connected to weight. These are often called anti-hedonics*, so they are reducing that desire cycle**, said Ricks.”_
[The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy | Scientific Reports (nature.com)](https://www.nature.com/articles/s41598-024-75965-2)
This large community-based cohort study investigates the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), specifically Liraglutide and Semaglutide, on the risk of developing psychiatric conditions such as depression, anxiety, and suicidal behaviors in patients with obesity. Utilizing post-marketing data, this research compares patients prescribed GLP-1 RAs (cases) with those not taking these medications (controls). The analysis spanned data from January 1, 2015, to December 31, 2023. To minimize selection bias, we employed 1:1 propensity score matching to account for demographic factors such as age, sex, race, and comorbidities. After matching, the study included 162,253 case and control patients. This study showed a significant association between GLP-1 RA treatment and an 98% increased risk of any psychiatric disorders. Notably, patients on GLP-1 RAs exhibited a 195% higher risk of major depression, a 108% increased risk for anxiety, and a 106% elevated risk for suicidal behavior. These findings underscore the critical need for physicians to thoroughly assess patient history before prescribing GLP-1 RAs and highlight the urgent requirement for further prospective clinical trials to fully understand the implications of GLP-1 RA use on mental health in the obese patient population.
[Rapid Treatment of Anhedonia With Pramipexole as Adjunct to Buprenorphine in OUD (psychiatrist.com)](https://www.psychiatrist.com/pcc/rapid-treatment-anhedonia-pramipexole-adjunct-buprenorphine-opioid-use-disorder/)
Depression with significant anhedonia can contribute to the development and complicate the treatment of opioid use disorder (OUD).1–3 Pramipexole, a dopamine receptor agonist with high affinity for D3 receptors and with possible additional anti-inflammatory properties, has been shown to be effective in treating anhedonic depression.4–7 We report a case in which pramipexole rapidly improved depression and anhedonia symptoms in a patient on buprenorphine and an antidepressant.
excerpts
I know it's long but very interesting imho
Tom